儿童大面积与次大面积肺栓塞的结局及危险因素:一项回顾性队列研究
该回顾性队列研究纳入加拿大两家儿童医院2000年1月1日至2016年12月31日连续170例年龄≤18岁急性肺栓塞患者,其中大面积37例(22%)、次大面积12例(7%)、非大面积121例(71%)。多变量分析仅肺栓塞严重程度与复合不良结局相关(OR 3.53,95%CI 1.69-7.36;P=0.011)。PESI预测30天死亡的ROC曲线下面积为0.76(95%CI 0.64-0.87),sPESI灵敏度100%、特异度30%。
要点
- 170例儿童肺栓塞中大面积37例(22%)、次大面积12例(7%)、非大面积121例(71%)。
- 肺栓塞严重程度与复合不良结局相关(OR 3.53,95%CI 1.69-7.36;P=0.011)。
- 儿童患者中PESI与sPESI需进一步调整以提高临床实用性。
核心结论
- 儿童大面积或次大面积肺栓塞的不良结局发生率高于非大面积肺栓塞。
- PESI和sPESI需进一步调整以提高其在儿童患者中的临床实用性。
研究设计与样本
- 回顾性队列研究,纳入加拿大两家儿童医院2000年1月1日至2016年12月31日连续170例年龄≤18岁、经影像学或病理学客观诊断的急性肺栓塞患者。
- 排除标准为未经影像学或病理学确认肺栓塞的猝死及非血栓栓塞性肺栓塞。
- 主要结局为肺栓塞相关死亡与肺栓塞复发或进展的复合不良结局。
主要发现
- 170例中大面积37例(22%)、次大面积12例(7%)、非大面积121例(71%)。
- 大面积或次大面积患者较非大面积患者更年轻(中位年龄12.5岁[IQR 0.6-15.1] vs 14.4岁[9.3-16.1],p<0.0001)。
- 大面积或次大面积患者较非大面积患者更常合并心脏病(16例[33%] vs 17例[14%],p=0.009)。
- 大面积或次大面积患者较非大面积患者更多置入中心静脉导管(29例[59%] vs 48例[40%],p=0.027)。
- 大面积或次大面积患者较非大面积患者更常采用积极治疗方式(22例[45%] vs 7例[6%],p<0.0001)。
临床怎么用
- 原文结论指出儿童大面积或次大面积肺栓塞的不良结局发生率高于非大面积肺栓塞。
- 原文结论指出PESI和sPESI需进一步调整以提高其在儿童患者中的临床实用性。
局限性
- 原文在解释部分指出PESI和sPESI需进一步调整以提高其在儿童患者中的临床实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about severe pulmonary embolism in children. We aimed to report pulmonary embolism outcomes, identify risk factors for unfavourable outcomes, and evaluate the discriminative ability of two clinical-severity indices in children. METHODS: In this retrospective cohort study, we included consecutive patients aged 18 years or younger with acute pulmonary embolism, objectively diagnosed radiologically or pathologically, between Jan 1, 2000, and Dec 31, 2016, from two Canadian paediatric hospitals (The Hospital for Sick Children, Toronto, ON, and the Children's Hospital of Eastern Ontario, Ottawa, ON). Exclusion criteria were sudden death without radiological or pathological pulmonary embolism confirmation and non-thromboembolic pulmonary embolism. The primary outcome was a composite of unfavourable outcomes of pulmonary embolism-related death and pulmonary embolism recurrence or progression. Potential predictors of the composite unfavourable outcome (ie, age at pulmonary embolism diagnosis, sex, underlying cardiac disease, severity of the pulmonary embolism, presence of a central venous catheter, associated venous thromboembolism, family history of thrombosis, treatment modalities, thrombophilia, obesity, and recent surgery) were explored with logistic regression. We calculated pulmonary embolism severity index (PESI) and simplified PESI (sPESI) using age-adjusted parameters; we estimated the ability of PESI and sPESI to predict mortality using receiver-operating characteristic (ROC) curve analysis. FINDINGS: Of the 170 patients included, 37 (22%) had massive, 12 (7%) submassive, and 121 (71%) non-massive pulmonary embolism. Patients with massive or submassive pulmonary embolism were younger (median age 12·5 years [IQR 0·6-15·1] vs 14·4 years [9·3-16·1], p<0·0001), more likely to have a cardiac condition (16 [33%] vs 17 [14%] patients, p=0·009), and had more central venous catheters (29 [59%] vs 48 [40%] patients, p=0·027) than patients with non-massive pulmonary embolism. Aggressive treatment modalities were more commonly used in massive or submassive pulmonary embolism (22 [45%] vs 7 [6%] patients, p<0·0001). Of the predictors tested, only pulmonary embolism severity was associated with the composite unfavourable outcome in the multivariable analysis (odds ratio 3·53, 95% CI 1·69-7·36; p=0·011). The area under the ROC curve for PESI to predict 30-day mortality was 0·76 (95% CI 0·64-0·87). Sensitivity of sPESI was 100% and specificity was 30%. INTERPRETATION: Massive or submassive pulmonary embolism led to higher rates of unfavourable outcomes than non-massive pulmonary embolism in children. Further adaptations of PESI and sPESI are required to improve their clinical usefulness in paediatric patients. FUNDING: Trainee Start-Up Fund (The Hospital for Sick Children).
引用
- Pelland-Marcotte MC, Tucker C, Klaassen A, et al. Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study. Lancet Haematol. 2019. PMID: 30772417. doi:10.1016/S2352-3026(18)30224-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。